Abstract | BACKGROUND:
Cutaneous lupus erythematosus (CLE) can be a severe disease, characterized by extensive, disfiguring lesions and a relapsing course. Thalidomide is known as an effective treatment for CLE, however, its use is restricted by its potential side-effects. Nevertheless, it remains a valuable option to consider. Therefore, it is important to report new clinical experiences. METHODS: The data of 30 patients with refractory CLE, who were treated with thalidomide, were retrospectively analyzed. The response rate was categorized as complete, partial or no response. The relapse rate and the occurrence of side-effects were registered. RESULTS: Six patients prematurely discontinued treatment because of side-effects. The response rate was 100% in the remaining 24 patients, including 20 patients (83%) with complete response and 4 (27%) with partial response. Clinical relapse was frequent (73%) and occurred between 3 and 24 weeks after withdrawal of thalidomide. Nine patients (30%) developed peripheral neuropathy. In the majority, there was no complete resolution of the neuropathy-associated symptoms after stopping thalidomide. One patient developed a thrombosis in an artery stent. CONCLUSION:
|
Authors | Isabelle Baret, Petra De Haes |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 26
Issue 2
Pg. 173-7
(Apr 2015)
ISSN: 1471-1753 [Electronic] England |
PMID | 24731053
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Female
- Humans
- Lupus Erythematosus, Cutaneous
(drug therapy)
- Male
- Middle Aged
- Recurrence
- Retrospective Studies
- Thalidomide
(adverse effects, therapeutic use)
- Treatment Outcome
- Young Adult
|